יחס מחיר לרווח Bluejay Diagnostics Corp (BJDX)
Bluejay Diagnostics (BJDX) specializes in the rapid diagnosis of critical pathologies, leveraging its patent-protected Symphony system. Stringent FDA requirements and unique software for portable testing create significant barriers to entry for new players. Business success depends on instrument accuracy and the demand for early detection of diabetes and sepsis. This chart of the current market value on GURU.Markets confirms these factors, standing at -0.20.
פילוחים אנליטיים של חברת Bluejay Diagnostics
The P/E ratio reflects the market consensus on the fair value of a business by relating the share price to net income. By analyzing the market P/E level of a company, an investor assesses the speed of capital return and the risk of overpayment. The multiple is calculated by dividing the market capitalization by annual income. For Bluejay Diagnostics (BJDX), this metric characterizes market expectations regarding the expansion of the Symphony system. A high valuation here is justified by the potential for implementing rapid sepsis diagnostics into emergency medicine.
